CN1055849C - Glossy privet leaf extract with regulating blood fat and lowering blood sugar function, its separating method and use - Google Patents
Glossy privet leaf extract with regulating blood fat and lowering blood sugar function, its separating method and use Download PDFInfo
- Publication number
- CN1055849C CN1055849C CN96101656A CN96101656A CN1055849C CN 1055849 C CN1055849 C CN 1055849C CN 96101656 A CN96101656 A CN 96101656A CN 96101656 A CN96101656 A CN 96101656A CN 1055849 C CN1055849 C CN 1055849C
- Authority
- CN
- China
- Prior art keywords
- ligustri lucidi
- separator
- folium ligustri
- alcohol
- blood fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to an outlier of ligustrum leaves having the functions of regulating blood fat and reducing blood sugar. The ligustrum leaves are mainly used as raw materials, and yellowish white powder is prepared by the steps of ethanol extraction, water washing for extractum, ethanol dissolution, decolorization, ethanol elimination, etc. The yellowish white powder is used as a main ingredient, and the medicine for regulating blood fat and reducing blood sugar can be prepared. Experiments of pharmacology, toxicology, etc. show that the extractive and a preparation thereof can regulate blood abnormality, prevent and cure atherosclerosis and cure type II diabetes.
Description
The present invention relates to a kind of Folium Ligustri Lucidi separator, its separation method and the accent blood fat, the hypoglycemic drug that prepare as effective ingredient with them.
Fructus Ligustri Lucidi is an Oleaceae Ligustrum plant, and its dry fruit is a Fructus Ligustri Lucidi, is Chinese medicine, and effect is invigorating the liver and kidney, strong waist, and crow must, make eye bright.The Folium Ligustri Lucidi, the effect of being put down in writing in the Compendium of Material Medica is " remove wind loose blood, subduing swelling and relieving pain, control head's dusk pain, all malignant boil are swollen " etc.; The Folium Ligustri Lucidi is arranged in " Guizhou side's medicine among the people collection ", and " external application ends hemorrhage due to wound, and anti-inflammation detumescence is controlled burn and scald; But emesis blood is coughed in cough-relieving for oral administration " record.The domestic people of having of the seventies carried out research to the chemical constituent of the Folium Ligustri Lucidi, the marquis who publishes as 1976.1 " Chinese herbal medicine communications " meets written " Folium Ligustri Lucidi The Chemical Constituents ", disclose in the literary composition from the alcohol extract of the Folium Ligustri Lucidi, separate two kinds of acicular crystals, through identifying, one is a mannite, is the effective ingredient of cough-relieving; It two is ursolic acid (Ursolie acid), and the author fails to point out its pharmacological action.To the present invention, more domestic medical institutions such as Sichuan Zigong City are prevented and treated the water decoction that chronic tracheitis cooperative groups etc. is mainly utilized the Fructus Ligustri Lucidi branch and leaf, the treatment chronic tracheitis.
Purpose of the present invention has to provide at two: one and has the Folium Ligustri Lucidi separator of transferring blood fat, hypoglycemic activity; Two to provide with Folium Ligustri Lucidi separator be accent blood fat, the hypoglycemic drug of main component preparation.
The present invention is a raw material with the exsiccant Folium Ligustri Lucidi, through alcohol reflux, extraction, ethanol extract, after boiling water washing, its water-insoluble is molten through alcohol, decolouring, remove step such as alcohol, a kind of yellowish white powder of gained is Folium Ligustri Lucidi separator.
The embodiment of preparation Folium Ligustri Lucidi separator from the Folium Ligustri Lucidi is described in detail in detail below:
Embodiment: take by weighing dry Folium Ligustri Lucidi 50KG, in the multipotency extraction pot of packing into, add alcohol reflux 2 times, for the first time add 6 times of amounts of ethanol, reflux, extract, 2 hours adds 4 times of amounts of ethanol for the second time, reflux, extract, 1 hour merges 2 times filtrate, reclaims ethanol to the extractum 7.8KG that weighs.
Get extractum in enamel pot, heating boils off remaining ethanol, add water and be about 25 times of extractum, boiling washing 15-20 minute, after the cooling, put centrifuge and dry, water-insoluble, dry, 80 ℃ of oven dry, 2.2KG weighs.
Get above-mentioned water-insoluble 2.2KG in the multipotency extraction pot, add ethanol and be 50 times of water-insoluble, reflux makes dissolving, add the 0.5-1.0% active carbon, reflux decolour 30 minutes, filtered while hot is removed pure evaporate to dryness with filtrate and is got yellowish white powder that is Folium Ligustri Lucidi separator.
Above-mentioned technology abandoned at present in plant amedica research in this compounds extraction separation process a large amount of use environmental pollutions such as ether, benzene, chloroform serious, produce unsafe class organic solvents, only adopt the second alcohol and water, make easy and safe to operate, be convenient to commercial production, equipment there is not specific (special) requirements, pollution-free, steady quality, average yield height, content of ursolic acid is not less than 70% in the Folium Ligustri Lucidi separator.
Be yield and content below with three batches of Folium Ligustri Lucidi separators of prepared of the present invention.
| The project lot number | The crude drug place of production | Inventory (KG) | Extractum (KG) | Water-insoluble (KG) | Folium Ligustri Lucidi separator (KG) | Ursolic acid content (%) | Yield (‰) |
| 910703 | Xianning,hubei | 50 | 7.7 | 2.2 | 0.61 | 71.2 | 12.2 |
| 910704 | 50 | 8.0 | 2.2 | 0.78 | 72.0 | 15.2 | |
| 910705 | 50 | 7.8 | 2.0 | 0.63 | 74.2 | 13.5 |
Through to above-mentioned Folium Ligustri Lucidi separator, develop the relevant requirements of declaring according to Ministry of Public Health new drug (Chinese medicine) two classes, the research of carrying out aspects such as pharmacology, toxicity is as follows:
One, pharmacodynamic study:
1. transfer the blood fat experimental study:
(1) experimental hyperlipidemia rat and rabbit all there are tangible reduction TG, TC, LDL-C and VLDL-C (P＜0.01) and the effect that improves HDL-C (P＜0.01), and can reduce the atherosclerosis AI index of experimental animal models.
(2) compare with the clofibrate matched group, crude drug high dose (1000MG/KG) drug effect is better than clofibrate, and middle dosage (500MG/KG) is suitable with the clofibrate drug effect.
(3) blood lipid level to normal rat and rabbit does not have obvious influence (P＞0.05).
2. blood sugar lowering experimental study
(1) the diabetes rat model that streptozotocin (STZ) is brought out, and three various dose (250MG/KG, 500MG/KG 1000MG/KG) all have obvious functions of blood sugar and reduce amount of drinking water, the effect of voided volume and glucose in urine, and three dosage present a certain amount of effect relationship.Relatively drug effect is suitable for low dose group and insoral matched group, after one week of drug withdrawal, still keeps certain hypoglycemic activity.
(2) (30MG/KG, 60MG/KG 100MG/KG) all have obvious functions of blood sugar, also present a certain amount of effect relationship to three various dose of diabetes white mice model of model induced by alloxan.
(3) normal size white mouse blood sugar level there is not influence.
Two, general pharmacology is learned research:
1. to action of nervous system
With 250,500, the dosage of 1000MG/KG is to the administration of NIH kind mice lavage, proves all with Irw in staging and the test of photoelectric counting method that autonomic activities was not had obvious influence in continuous 7 days.
2. to the cardiovascular system effect
With 250,500, the dosage of 1000MG/KG was to SD kind rat gastric infusion, continuous 7 days.After the anesthesia, write down its heart rate, electrocardiogram and blood pressure and the blank group does not relatively have notable difference.
3. to the respiratory system effect
Rat is measured respiratory frequency earlier under the anesthesia situation, irritate stomach after one hour, and respectively with crude drug 250,500,1000MG/KG dosage gastric infusion continues to be determined at respiratory frequency in the respiratory, basically identical before and after result and the administration.
Three, toxicological study
1. large and small white mouse acute toxicity test
20 of 10 of rat and white mice, male and female half and half, it (is 320MG/20G that every filling stomach gives test sample 0.5ML, suitable 16000MG/KG), in observing administration 14 days the animal feed normal, weight increase, all sound, dissect all animals after 14 days, do not find that the major organs heart, liver, spleen, lung, kidney, intestinal etc. have macroscopic pathological changes, therefore think that this product is nontoxic substantially.
2. rat long term toxicity test
Get height that body weight 130-160G rat is divided into crude drug at random, in
1, in
2, low four kinds of dosage, six groups of insoral and blank groups etc.The dosage of crude drug---high dose is 7500MG/KG (is equivalent to Coming-of-Age Day consumption 250 times), in
1Dosage is 1500MG/KG (be equivalent to Coming-of-Age Day consumption 50 times), in
2Dosage is 750MG/KG (be equivalent to Coming-of-Age Day consumption 25 times), low dosage is 300MG/KG (is equivalent to Coming-of-Age Day consumption 10 times), insoral is 75MG/KG (is equivalent to Coming-of-Age Day consumption 25 times), every group of 20 male and female half and half, carried out scheduling to last trimestral rat long term toxicity test research, the result shows:
(1) this product height, in
1, in
2, in low four groups of successive administrations three months the animal feed normal, weight increase.
(2) hemogram, liver, renal function blood glucose, glucose in urine and routine urinalysis in the body are not all had obvious influence, convalescent period is not also seen the continuity infringement.
(3) dissect rat and do not see that the major organs heart, liver, spleen, lung, stomach, intestinal have obvious macroscopic pathological changes, drug withdrawal 24 hours and convalescent period, each organizes the vitals heart, liver, spleen, lung, warm organ coefficient basically identical, no enlargement or the pathological changes of dwindling.
(4) side effect of loose stool appears in insoral group part rat.
3. Canis familiaris L. long term toxicity test
8 of mongrels were selected in this test in six months by a definite date for use, divide equally administration group and blank group, every group of four male and female half and half, the administration group with the dosage of crude drug 900MG/KG (be equivalent to clinical Coming-of-Age Day consumption 1500MG 30 times) with the feeding method administration, administration is 6 days weekly, dosage with every month body weight change in accordance with regulations dosage adjust, test shows:
(1) general symptom of animal and body weight are observed, and administration treated animal spirit, activity, hair, feces, diet are normal.After 4th month, the body weight phenomenal growth, every month straight line of blank group body weight increases.
(2) peripheral hemogram
Each phase of administration (1-6) does not have obvious influence to the hemoglobin value, and numeration of leukocyte and class ratio values fluctuateed in normal range.
(3) heating function is influenced
The serum glutamic pyruvic transminase value of crude drug group, blood urea nitrogen is consistent with the blank group.Convalescent period does not also have significant change, the serum alkaline phosphatase value, and the lactic acid dehydrogenase value, the creatinine value is all in normal range.
(4) gross examination of skeletal muscle and pathology microscopy
The test back gross examination of skeletal muscle major organs heart, liver, spleen, lung, kidney, stomach, intestinal anatomical position are normal, no dystopy, and antiposition, deformity, splenomegaly or dwindle and the visible pathological changes of other naked eyes, the pathology microscopy is the result show, do not have obvious pathological change.
Result of the test to sum up, this product is taken no overt toxicity reaction and infringement for a long time with 900MG/KG.
Below be the quality standard of Folium Ligustri Lucidi separator:
1. character: the yellowish white powder, gas does not have lightly seasoned;
2. differentiate: (1) carries out identification by triterpenoid compound.
(2) press the thin layer chromatography that Chinese Pharmacopoeia is stipulated, get crude drug and ursolic acid reference substance solution point and on same lamellae, carry out the chromatography contrast, show identical rose speckle, R in the relevant position
fValue is 0.75-0.85.
3. check: be defined in 105 ℃ of dry constant weights by Chinese Pharmacopoeia, subtract weight loss and be no more than 5%.
4. assay: adopt vanillin-perchloric acid colorimetry and ursolic acid standard substance curve to contrast, content of ursolic acid in the mensuration crude drug.
Function with cure mainly: this product can be used for adjusting dyslipidemia and prevents and treats atherosclerosis, the treatment type ii diabetes.
6. usage and consumption: one day three times, a 300MG, 8 weeks were a course of treatment.
7. storage: put shady and cool dry place and preserve.
8. effect duration: tentative 2 years.
With above-mentioned Folium Ligustri Lucidi separator is that main component can be made capsule, tablet, oral liquid etc. by general formulation method, and preparation capsule embodiment is described in detail in detail below.
Embodiment: get Folium Ligustri Lucidi separator 5KG, put in the spherical tank, add 20 times of ethanol, heating makes dissolving, heat preservation for standby use; Take by weighing Polyethylene Glycol-600010KG, heat fused is poured above-mentioned Folium Ligustri Lucidi separator alcoholic solution in the Polyethylene Glycol-6000 that has melted into, stirs, and ethanol is reclaimed in congruent melting, and its eutectic cooling is solidified, and pulverizes, and crosses 40 mesh sieves, and is promptly encapsulated.
This capsule is carried out researchs such as pharmacology, toxicity according to the relevant requirements of new drug (Chinese medicine) two classes development application, and its result is consistent with the result of the test of Folium Ligustri Lucidi separator.
The capsule quality standard is as follows:
1. character: this product is a capsule, and content is a pale yellow powder, and gas do not have, lightly seasoned.
2. differentiate: (1) is got capsule content powder and is carried out identification by triterpenoid compound.
(2) press the thin layer chromatography that Chinese Pharmacopoeia is stipulated, get content and ursolic acid reference substance solution point and on same lamellae, carry out the chromatography contrast, show identical rose speckle, R in the relevant position
rValue is 0.75-0.85.
3. check: should meet the relevant every regulation (16 pages of appendix of Chinese Pharmacopoeia nineteen ninety version) under the capsule item
4. assay: adopt vanillin-perchloric acid colorimetry and ursolic acid standard substance curve to contrast, content of ursolic acid in the mensuration capsule.
Function with cure mainly: this product can be used for adjusting dyslipidemia and prevents and treats atherosclerosis, the treatment type ii diabetes.
6. usage and consumption: one day three times, one time three, 8 weeks were a course of treatment.
7. specification: every heavy 0.3G (containing Folium Ligustri Lucidi separator 0.1G) of capsule, * 30 of plastic-aluminum box packings
8. storage: put shady and cool dry place and preserve.
9. effect duration: tentative 2 years.
Claims (3)
1. medicinal Folium Ligustri Lucidi separator, it is characterized in that: the Folium Ligustri Lucidi through alcohol reflux, extraction, remove alcohol, get ethanol extract, after the boiling water washing, its water-insoluble is molten through alcohol, decolouring, remove alcohol, gained separator and ursolic acid reference substance solution are put on same lamellae and are contrasted, and show identical rose speckle at relative position, and Rf value is 0.75-0.85; And content of ursolic acid is not less than 70%.
2. the separation method of a Folium Ligustri Lucidi separator as claimed in claim 1 is characterized in that: the Folium Ligustri Lucidi through alcohol reflux, extraction, remove alcohol, ethanol extract, after the boiling water washing, its water-insoluble is molten through alcohol, decolouring, remove alcohol, promptly.
3. the application of a medicinal Folium Ligustri Lucidi separator as claimed in claim 1 in pharmacy is characterized in that: this separator is mainly used in preparation and has the medicine of transferring blood fat, hypoglycemic activity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96101656A CN1055849C (en) | 1996-02-29 | 1996-02-29 | Glossy privet leaf extract with regulating blood fat and lowering blood sugar function, its separating method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96101656A CN1055849C (en) | 1996-02-29 | 1996-02-29 | Glossy privet leaf extract with regulating blood fat and lowering blood sugar function, its separating method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1158254A CN1158254A (en) | 1997-09-03 |
| CN1055849C true CN1055849C (en) | 2000-08-30 |
Family
ID=5117174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96101656A Expired - Lifetime CN1055849C (en) | 1996-02-29 | 1996-02-29 | Glossy privet leaf extract with regulating blood fat and lowering blood sugar function, its separating method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1055849C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853637B (en) * | 2005-03-11 | 2010-05-12 | 中国药科大学 | Use of pentacyclic triterpene compound as glycogen phosphorylase inhibitor |
-
1996
- 1996-02-29 CN CN96101656A patent/CN1055849C/en not_active Expired - Lifetime
Non-Patent Citations (3)
| Title |
|---|
| 《中草药通讯》1976(1) 1976.1.30 侯遇成，女贞叶化学成分的研究 * |
| 《云南植物研究》1993,15(2) 1993.2.28 罗心毅等，小蜡精油的化学成分 * |
| 《云南植物研究》1993,15(2) 1993.2.28 罗心毅等，小蜡精油的化学成分;《中草药通讯》1976(1) 1976.1.30 侯遇成，女贞叶化学成分的研究 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1158254A (en) | 1997-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1283258C (en) | Medicine for preventing fibrous liver and preparing method thereof | |
| CN101011561B (en) | Modern traditional Chinese medicine oral preparation huanglianwendan decoction and production method thereof | |
| CN104623201B (en) | A kind of liver protection Elmination of toxicant and fat-lowering hypoglycemic medicine and its application | |
| CN108404062B (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method and application thereof | |
| CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
| CN105832794A (en) | Application of Gynura procumbens to production of medicine, healthcare food or functional food for preventing and treating hyperuricemia | |
| CN1899342A (en) | Oral medicine for treating diabetes and its use | |
| CN110075216B (en) | Food composition with auxiliary blood fat reducing, weight losing and liver protecting effects and preparation method, preparation and application thereof | |
| WO2013155995A1 (en) | Red yeast and kudzu root pharmaceutical composition for regulating blood lipids and preparation method therefor | |
| CN101933973B (en) | Medicament composition for preventing and treating liver damage | |
| CN1872252A (en) | Composition of active ingredients of alisma rhizome, and medical application | |
| CN107375430A (en) | A kind of curcumin composition with preventing and treating diabetes and complication | |
| CN101259191B (en) | Fat-reducing health products and producing method thereof | |
| CN1055849C (en) | Glossy privet leaf extract with regulating blood fat and lowering blood sugar function, its separating method and use | |
| CN1233377C (en) | Fat reducing Chinese drugs for treating simple obesity | |
| CN100336540C (en) | Medicine composition for treating hyperlipemia and its prepn | |
| CN1159029C (en) | Blood lipoid regulating medicine and its prepn | |
| CN1125106A (en) | Chang'an capsule and its preparation method and application | |
| CN109316565A (en) | A kind of blood-fat reducing composition and its preparation method and application | |
| CN101698094B (en) | Distillate for treating white vein diseases and preparation method thereof | |
| CN110538280A (en) | antidepressant confirmed by pharmacological activity and preparation method thereof | |
| CN108403906A (en) | A kind of pharmaceutical composition and preparation method thereof of prevention rheumatoid arthritis | |
| CN100579567C (en) | Use of Chinese medicine preparation in preparing medicine for defending coronary heart disease | |
| CN1042597C (en) | Vision-brighting and blood sugar decreasing composition and its produciton | |
| CN102743477A (en) | Traditional Chinese medicine preparation for treating hepatitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: In Hubei province Huangshi City Road 435003 No. 1 Huangshi 39 Pharmaceutical Co. Ltd. Patentee after: Huangshi 39 Pharmaceutical Co., Ltd. Address before: 435002 No. two, No.1 Textile Road, Hubei, Huangshi Patentee before: Sanjiu Huangshi City Pharmaceutical Factory |
|
| C56 | Change in the name or address of the patentee |
Owner name: CHINA RESOURCES SANJIU (HUANGSHI) PHARMACEUTICAL C Free format text: FORMER NAME: HUANGSHI 999 PHARMACEUTICAL CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: In Hubei province Huangshi City Road 435003 No. 1 39 Huarun (Huangshi) Pharmaceutical Co. Ltd. Patentee after: Huarun 39 (Huangshi) Pharmaceutical Co., Ltd. Address before: In Hubei province Huangshi City Road 435003 No. 1 Huangshi 39 Pharmaceutical Co. Ltd. Patentee before: Huangshi 39 Pharmaceutical Co., Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20000830 |
|
| EXPY | Termination of patent right or utility model |